Abstract. Exons 3 to 6 in the caspase 9 gene undergo alternative splicing in which the larger caspase 9 splice variant promotes apoptosis, in contrast to the dominant negative anti-apoptotic splice variant, the smaller caspase 9b. In this study, the regulation of the alternative splicing of caspase 9 pre-mRNA was examined in response to Emetine. Treatment of C33A cells, breast cancer MCF-7 cells and MCF-7/Adr cells with Emetine dihydrochloride upregulated the level of smaller caspase 9b mRNA and concomitantly decreased the mRNA level of larger caspase 9 in a dose-and time-dependent manner, indicating that Emetine desensitizes C33A, MCF-7 and MCF-7/Adr to cell death. In contrast, treatment of PC3 cells, a prostate cancer cell line, manifested an opposite effect: a greater production of the larger caspase 9 mRNA with a concomitant decrease of caspase 9b mRNA. Pretreatment with calyculin A, an inhibitor of protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A) blocked Emetine-induced alternative splicing in cells, in contrast to okadaic acid, a specific inhibitor of PP2A, demonstrating a PP1-mediated mechanism. These results suggest that the various splicing patterns of the caspase 9 gene that are regulated by chemotherapy reagents may contribute to the resistance or sensitization of the tumors to other cell death inducers.
Introduction
Apoptosis is a common and well-understood mechanism of cell death resulting from the activation of caspases through two primary pathways: i) via caspase 9 activation and a mitochondrial route to release cytochrome c, or ii) directly via caspase 8 to caspase 3 as a primary effector caspase. At least 14 caspases have been identified and characterized in mammalian cells. Caspases fall into two classes: initiator caspases (caspases 8, 9, 2 and 10) that exclusively cleave and activate other caspases, and effector caspases (caspases 3, 6 and 7) that cleave other proteins. Procaspases are activated by cleavage at the same consensus site, either by themselves or by other caspases. Other proteins targeted by caspases include inhibitory apoptotic proteins (IAPs), inhibitors of caspase-activated DNAase (ICADs), Bcl-2, signal pathway proteins, cytoskeletal proteins and DNA repair enzymes, including DNA-dependent protein kinases. These different target proteins of caspase result in apoptotic cell death. It has been shown more recently that one of the mechanisms of regulating the balance between proliferation and cell death is through alternative splicing of apoptotic genes. Deregulation of this balance represents a pro-tumorigenic principle or neuronal death in human carcinogenesis or neurodegenerative diseases (1) .
Splicing is a cellular process that removes introns from the pre-mRNA in eukaryotic genomes so that exons join together to form a mature mRNA. However, when the introns of a certain pre-mRNA are excised in more than one way, alternative splicing occurs, resulting in several possible mature mRNAs from one gene. Alternative pre-mRNA splicing is an essential mechanism for generating protein diversity (2) (3) (4) (5) . It is estimated that more than 60% of human genes undergo alternative splicing, leading to the production of diversified functional isoforms (6) . Alternative splicing is precisely regulated. Aberrant splicing may lead to human disorders, including growth hormone deficiency, spinal muscular atrophy (7, 8) and possibly tumors and neurodegenerations.
A number of pre-mRNAs for cell death signals, including caspase 9, one of the most significant factors in the apoptotic pathways, are alternatively spliced, yielding isoforms with opposing functions during programmed cell death (8) (9) (10) . Findings of various reports demonstrated that the alternative splicing of caspase 9 can be regulated by small molecules such as ceramide in cancer cells (11) , as well as by other biological molecules SRp30a (ASF/SF2), E2F and SC35 (12, 13) . To identify additional small molecules that are potentially used in cancer treatment to regulate caspase 9 splicing, we performed reverse transcriptase-polymerase chain reaction (RT-PCR) experiments in cells treated with 1,040 FDA-approved drugs and compounds. Emetine, a potent protein synthesis inhibitor in eukaryotes (14) , was found to downregulate pro-apoptotic caspase 9 and upregulate anti-apoptotic caspase 9b in C33A and MCF-7 cells, while in PC3 cells, an opposite effect was 
Materials and methods
Compounds. All chemicals including Emetine, calyculin A and okadaic acid were purchased from Sigma (St. Louis, MO, USA).
Cell culture. The human cervical carcinoma C33A cells were maintained in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% (vol/vol) fetal bovine serum (FBS), L-Glutamine and 1X penicillin-streptomycin. PC3 prostate cancer cells were cultured in RPMI supplemented with 10% (v/v) FBS, L-Glutamine and 1X penicillin-streptomycin. Human breast cancer cells MCF-7 and MCF-7/Adr were cultured in RPMI supplemented with 10% (v/v) FBS, L-Glutamine and 1X penicillin-streptomycin. All cells were maintained at less than 80% confluence under standard incubator conditions.
Emetine treatment. Emetine dihydrochloride hydrate (Sigma) with a stock solution concentration of 100 µM was used. Twenty-four hours prior to Emetine treatment, the cells were plated in 2 ml medium in 6-well plates at a density of 200,000 cells/well. The cells were treated with various concentrations of Emetine for 24 h for a dose-dependent study. For the time course experiment, cells were treated with 1.0 µM Emetine for various durations.
Protein phosphatase inhibitor treatment. Cells were pretreated with calyculin A or okadaic acid for 1 h. The media were removed. Fresh regular media with Emetine were added to treat cells for the duration of 24 h. RT-PCR was then carried out to examine caspase 9 splicing.
Reverse transcriptase-polymerase chain reaction. Total RNA was extracted from cultured cells using TRIzol reagent (Invitrogen Corp., Carlsbad, CA, USA) according to the manufacturer's instructions. Reverse transcription was carried out with 1 µg total RNA using Improm II reverse transcriptase (Promega, Madison, WI, USA) and oligo (dT) as the priming agent. Following incubation for 1 h at 42˚C, the reactions were terminated by heating at 70˚C for 15 min. To analyze alternative splicing of the caspase 9 gene, an upstream 5' primer (5'-GCTCTTCCTTTGTTCATCTCC-3') and a downstream 3' primer (5'-CATCTGGCTCGGGGTTACTGC-3') were used for PCR amplification (35 cycles at 94˚C, 30 sec; 55˚C, 30 sec; 72˚C, 1 min) with Choice Taq Blue Mastermix (Denville Scientific Inc., South Plainfield, NJ, USA). PCR products were separated and analyzed on agarose gels. This study was approved by the ethics committee at Nantong University, Nantong, Jiangsu, China.
Results
Emetine regulates the alternative splicing of caspase 9 pre-mRNA. To identify small molecules that regulate alternative splicing, 1,040 FDA-approved drugs and compounds were screened using RT-PCR in C33A cells, a cervical cancer line. As described in our previous study, Emetine regulated alternative splicing of the Bcl-x gene (15) . Notably, Emetine was also found to increase the smaller caspase 9b mRNA with a concomitant increase of the larger caspase 9 mRNA (Fig. 1) . To further validate our findings, C33A cells were treated with various concentrations of Emetine or for different time durations. A decrease in the ratio of caspase 9/ caspase 9b was observed (Fig. 1A) . In our previous studies, Emetine was also found to alter splicing of the Bcl-x gene (15) but not the tau, SMN or BACE1 genes, indicating its relative specificity on caspase 9 and Bcl-x splicing. To further validate whether Emetine regulates splicing in the caspase 9 gene and to evaluate whether regulation of caspase 9 splicing has potential relevance to cancer therapy, we examined the (Fig. 1C and D) , regulation of caspase 9 splicing was found to be slightly less pronounced than in C33A cells. However, the pattern of the regulation was similar to that observed in C33A cells; i.e., an increase of caspase 9b and a decrease of caspase 9. Conversely, in PC3 (a prostate cancer cell line) cells (Fig. 2) , an opposite effect of Emetine on caspase 9 splicing was noted: an increase of caspase 9 and a decrease of caspase 9b. The effects of Emetine on the pre-mRNA processing of caspase 9 in PC3 cells were time course-and dose-dependent ( Fig. 2A and B) .
Emetine exerts its effect on caspase 9 splicing, via protein phosphatase 1 (PP1).
Previous studies showed that ceramide and Emetine affect the splicing of Bcl-x in a phosphorylationdependent pathway. To examine whether Emetine exerts the effects on caspase 9 splicing in a similar manner, C33A and PC3 cells were treated with phosphatase inhibitors calyculin A and okadaic acid. We found that 5 µM calyculin A, an inhibitor of both protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A), blocked the Emetine effects on caspase 9 alternative splicing in C33A and PC3 cells (Fig. 3 , comparing +Emetine with +Emetine/calyculin A). To establish whether PP1 or PP2A was the Emetine-responsive protein phosphatase that regulates caspase 9 alternative splicing, C33A and PC3 cells were pretreated for 1 h with 5 µM okadaic acid, a selective PP2A inhibitor. Pretreatment with okadaic acid had no effect on caspase 9 alternative splicing (Fig. 3 , comparing +Emetine with +Emetine/okadaic acid). Taken together, these results suggest that PP1 mediates the effects of Emetine on the alternative splicing of caspase 9.
Discussion
We previously described that Emetine regulated alternative splicing of Bcl-x, increasing the smaller pro-apoptotic Bcl-xS isoform and decreasing the larger anti-apoptotic Bcl-xL isoform, resulting in the possible sensitization of tumor cells to chemotherapy (15) . We further demonstrated that Emetine modulated Bcl-x splicing by affecting PP1 phosphatase. These results were consistent with an earlier study (11) that a second chemotherapy agent, ceramide, also affected Bcl-x splicing through PP1. Notably, the authors of that study also demonstrated that in addition to Bcl-x, ceramide regulated alternative splicing of the caspase 9 gene through a similar mechanism, leading to an increase of the larger pro-apoptotic caspase 9 and a decrease of the smaller anti-apoptotic caspase 9b. Based on their studies, it appears that there is a synergetic effect on splicing of Bcl-x and caspase 9 in A549 cells, leading to an increase of pro-apoptotic isoforms for the two genes and to sensitization of A549 cells to death inducers.
However, in contrast to the effects of ceramide on the splicing of Bcl-x and caspase 9 in A549 cells, i.e., an increase of the pro-apoptotic forms of Bcl-x (Bcl-xS) and caspase 9 (caspase 9) genes, this study revealed that Emetine has an opposite effect on the alternative splicing of caspase 9 in different tumor cell lines. In PC3 cells, Emetine increased pro-apoptotic caspase 9 (full-length) with a concomitant decrease of anti-apoptotic smaller caspase 9b, while in C33A and MCF-7 cells Emetine increased anti-apoptotic caspase 9b with a decrease of the full-length pro-apoptotic caspase 9 (Figs. 1-3) . The results in C33A and MCF-7 cells were unexpected, as Emetine had been considered to be one of the potential chemotherapeutic agents assumed to induce cell 
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death. As discussed in our earlier study (15) , Emetine acts as an effective chemotherapeutic agent by increasing the lifespan of tumor-bearing mice (16, 17) and thus has the possibility for clinical advantage (18, 19) . However, although no previous study explains the mechanism responsible for the anti-tumor effect of Emetine, our results regarding the effects of Emetine on Bcl-x splicing (15) suggested that Emetine promoted the expression of pro-apoptotic proteins by regulating alternative splicing. However, based on the results in this study, we deduce that Emetine sensitizes cells to chemotherapy in certain types of tumors but does not sensitize them in others by regulating alternative splicing of caspase 9 in various ways. It is possible that a balance exists among apoptotic genes including Bcl-x and caspase 9. In addition, it appears that chemotherapy that is effective for one type of cancer may not be effective for others, although the target is the same (such as caspase 9). Our studies provide insights into the future treatment of cancers by targeting alternative splicing.
